PubTransformer

A site to transform Pubmed publications into these bibliographic reference formats: ADS, BibTeX, EndNote, ISI used by the Web of Knowledge, RIS, MEDLINE, Microsoft's Word 2007 XML.




PMID- 29715159
OWN - NLM
STAT- MEDLINE
DCOM- 20180508
LR  - 20180508
IS  - 1791-7530 (Electronic)
IS  - 0250-7005 (Linking)
VI  - 38
IP  - 5
DP  - 2018 May
TI  - Utilization of Hysterectomy Following Chemoradiation for IB2/IIA2 Cervical Cancer
      in the National Cancer Data Base.
PG  - 3175-3179
AB  - BACKGROUND/AIM: Performing hysterectomy following chemoradiotherapy (CRT) for
      IB2/IIA2 cervical cancer is highly controversial. This study evaluated national
      practice patterns in utilization of post-CRT hysterectomy in the United States
      compared to CRT alone, as well as outcomes. MATERIALS AND METHODS: The National
      Cancer Database was queried for patients with newly diagnosed IB2/IIA2 cervical
      cancer. Multivariable logistic regression analysis assessing factors predictive
      of undergoing post-CRT hysterectomy. Kaplan-Meier analysis evaluated overall
      survival (OS) and Cox proportional hazards modeling determined variables
      associated with OS. RESULTS: Altogether, 1,691 patients met the inclusion
      criteria; 1,551 (92%) received CRT alone, and 140 (8%) underwent subsequent
      hysterectomy. Patients with tumors >/=8 cm were more likely to undergo
      hysterectomy. Patients who underwent additional hysterectomy, likely a
      higher-risk cohort, displayed OS comparable to those receiving CRT alone.
      CONCLUSION: Greater tumor size was associated with hysterectomy following CRT for
      IB2/IIA2 cervical cancer in the United States. These patients achieve OS
      comparable to those receiving standard-of-care CRT.
CI  - Copyright(c) 2018, International Institute of Anticancer Research (Dr. George J. 
      Delinasios), All rights reserved.
FAU - Haque, Waqar
AU  - Haque W
AD  - Department of Radiation Oncology, Houston Methodist Hospital, Houston, TX, U.S.A.
      [email protected]
FAU - Verma, Vivek
AU  - Verma V
AD  - Department of Radiation Oncology, Allegheny General Hospital, Pittsburgh, PA,
      U.S.A.
FAU - Butler, E Brian
AU  - Butler EB
AD  - Department of Radiation Oncology, Houston Methodist Hospital, Houston, TX, U.S.A.
FAU - Teh, Bin S
AU  - Teh BS
AD  - Department of Radiation Oncology, Houston Methodist Hospital, Houston, TX, U.S.A.
LA  - eng
PT  - Journal Article
PL  - Greece
TA  - Anticancer Res
JT  - Anticancer research
JID - 8102988
SB  - IM
MH  - Adult
MH  - Aged
MH  - Combined Modality Therapy/*methods
MH  - Female
MH  - Humans
MH  - Hysterectomy/*utilization
MH  - Kaplan-Meier Estimate
MH  - Middle Aged
MH  - Proportional Hazards Models
MH  - United States
MH  - Uterine Cervical Neoplasms/drug therapy/radiotherapy/*surgery
OTO - NOTNLM
OT  - *Cervical cancer
OT  - *chemotherapy
OT  - *hysterectomy
OT  - *radiation therapy
EDAT- 2018/05/02 06:00
MHDA- 2018/05/09 06:00
CRDT- 2018/05/02 06:00
PHST- 2018/03/14 00:00 [received]
PHST- 2018/04/17 00:00 [revised]
PHST- 2018/04/18 00:00 [accepted]
PHST- 2018/05/02 06:00 [entrez]
PHST- 2018/05/02 06:00 [pubmed]
PHST- 2018/05/09 06:00 [medline]
AID - 38/5/3175 [pii]
AID - 10.21873/anticanres.12581 [doi]
PST - ppublish
SO  - Anticancer Res. 2018 May;38(5):3175-3179. doi: 10.21873/anticanres.12581.